JPS60260520A - Drug composition - Google Patents

Abstract

PURPOSE:A drug composition such as ones for circulatory organs, metabolic drugs, etc., comprising Angelica shikokiana Makino as an active ingredient. CONSTITUTION:A drug composition for circulatory organs or useful as metabolic drugs, comprising a component (bergapten, psoralen, 3'-acetoxy-4'-angeloxy-3', 4'-dihydroxyseselin, and 3'-acetoxy-4'cenecioxy-3',4'-dihydroxyseselin) contained in root and stalk part of cultivated system of Angelica shikokiana Makino that is a plant belonging to the family Umbeliferae as an active ingredient. In Angelica shikokiana Makino, its stalk or roots are dried and powdered, its stalk and roots are extracted with an organic solvent such as ethyl acetate, etc. to give essence, which is used as an active ingredient, which is pharmaceutically manufactured into a tablet, pill, capsule, etc. It has an inhibitory action on the action of noradrenaline, catecholamine and further preventing action on accumulation of fats in liver and accumulation of peroxide.

Description

DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a pharmaceutical drug, particularly a drug for the cardiovascular system and metabolic system, which contains a physiologically active substance contained in Japanese ginseng as an active ingredient.

[Conventional technology]

Conventional medicines containing plant ingredients as active ingredients have long been known as Chinese herbal medicines.

[Problem that the invention seeks to solve]

Many traditional Chinese medicines each have unique active ingredients,
Although they are used for the treatment and prevention of specific diseases depending on their active ingredients, there are various drawbacks such as the range of indications, the amount of use, and the combination with other drugs. Furthermore, many of the medicinal plants used as raw materials are difficult to obtain due to the cultivation environment.

[Means for solving problems]

The present invention relates to the root of Japanese mountain ginseng, which is a new crop belonging to the cultivation lineage of Inutoki, a perennial plant of the Umbelliferae family.

They discovered that the components contained in the stems act on the human circulatory system and metabolic system, dilating blood vessels and inhibiting the accumulation of hepatic lipids. They discovered a certain point and completed the present invention.

The present invention is a pharmaceutical composition for the cardiovascular system and metabolic system containing powder or extract of Japanese mountain ginseng.

The Japanese mountain ginseng used in the present invention belongs to the Apiaceae family (On+bel 1
Ang ferae) is a perennial plant of Ang.
It is a cultivated plant of the cultivar Elicashikokiana Makino, and the length of the main stem extension when fully ripe is approximately 1.
20cm~°130(2), one inflorescence grows epiphytically at the apex of the main stem and lateral branches, and is a plural inflorescence. The diameter of the inflorescence on the main stem is about 20 cm, and it blooms around June.

In the present invention, the stems or roots of the Japanese ginseng are dried and powdered, or the extract obtained by extracting the stems and roots with an organic solvent such as ethyl acetate is used as an active ingredient.

The pharmaceutical agent of the present invention is provided as a medicine or a health food by drying the stem and root of the Japanese mountain ginseng and making it into a preparation such as a tablet, nine tablets, or a capsule.

Excipients such as starch, sugar, mannitol, cellulose derivatives such as carboxymethylcellulose, alginates, A binder such as gelatin, polyvinylpyrrolidone, a lubricant such as glycerin, etc. are added as appropriate to form a preparation by a conventional method.

In addition, when making it into a health food, in addition to the main ingredients, add garlic, egg yolk oil, various vitamins, etc. used in other health foods, and add the above excipients, binders, lubricants, etc. and capsules.

The pharmaceutical composition of the present invention can be made into tablets, gunpowders, capsules, etc. by adsorbing the Japanese ginseng extract to the excipient or adsorption carrier such as kaolin or bentonite.

The components of Japanese ginseng which are the active ingredients of the present invention are bergapten, psoralen, 3'-acetoxy-41-angeloxy 3', 4'-dihydroceserine and 3'-acetoxy-4'-senesioxy-3'.

4'-dihydroxycecerine.

〔Example〕

The stems and roots of Japanese ginseng are dried and made into powder.

410 oz of this powder, garlic powder and 9 oz of egg yolk oil were filled into capsules.

This capsule is usually administered orally by adults in 3 to 6 capsules per day.

(Effect of the invention) Japanese ginseng, which is the active ingredient of the present invention, has a remarkable effect of suppressing the effects of noradrenaline and catecholamines, and also has an effect of preventing fat accumulation in the liver and lipid peroxide accumulation in the body. It is something.

Next, we will describe a test that shows its effectiveness.

Test Example 1゜Effect of the drug of the present invention on liver damage and hyperlipidemia A. Experimental materials and method A. Experimental material 1. Drugs used. 2. Japanese ginseng 2. Animals used: Wistar male rats ( The rats (weighing 200 to 220 g) were taken from Charles River and preliminarily reared for one week at a room temperature of ±1°C and a humidity of 5% ±5%, and experiments were conducted using healthy rats with good fur.

3. Lipid peroxide: While injecting oxygen into corn oil,
When heated at 180° to 200°C for 1 hour, lipid peroxide increases tenfold. An experiment was conducted using the peroxidized corn oil thus prepared.

B. Experimental method 1: Effect of Japanese ginseng on lipid peroxide-administered rats Wistar male rats (body weight 340~
Peroxidized corn oil (360 g) was forcibly administered orally for 11 days between 9 and 10 a.m. at a dose of 3 m, 17 animals/time. Blood and liver were collected immediately after stratification 1.5 hours after the final administration.

The experimental groups were as follows.

Normal group: Oriental yeast solid feed and water were freely available.

Control group: The animals were given free access to Oriental Yeast ■ solid feed and water, and peroxidized corn oil was administered at 3 mβ/animal once a day.

Test Group 1: The animals were given free access to Oriental Yeast ■ solid feed and water, and Japanese mountain ginseng was suspended in peroxidized corn oil at a concentration of 200 μg/kg and forcibly administered once a day.

Test group 2: Oriental yeast solid feed and water were given ad libitum, and Japanese mountain ginseng was suspended in peroxidized corn oil at a concentration of 100 kg/kg and forcibly administered orally once a day. .

2. Plasma enzymes, lipids, and liver lipids were measured using the following reagents.

Serum transamylase (GOT, GPT) S, TA test (Wako) Neutral fat (T, G) Mixed solvent extraction method Total cholesterol (T, C) Cholesterol B test (Wako) Lipid peroxide (Lipoperoxide) TBA method HDL- Cholesterol (HDL-Cho>HDL-C
Set (Daiichi Chemical) 3. Experiments and Experiment Results Rats were divided into four groups, and the following experiments were conducted for each group.

A group of five rats was raised for 11 days without administering peroxidized corn oil Japanese ginseng, and this group was designated as the Zhenrai group.

3 mβ of peroxidized corn oil was applied to the pouches and throats of 4 animals per group.
The control group was a group in which the drug was forcibly administered orally once a day for 11 days.

4 rats per group Suspended 200 mg/kg of Honzan ginseng in peroxidized corn oil and administered it once a day at 9-10 a.m.
A group to which 3 ml/mouse was forcibly administered orally for 11 days was designated as test group 1.

A group of 4 rats in which 100 μg/kg of Japanese mountain ginseng was suspended in peroxidized corn oil and 3 ml/rat was forcibly administered orally once a day between 9 and 10 a.m. for 11 days. was designated as test group 2.

Serum GOT, GPT, total cholesterol, neutral fat, lipid peroxide, and HDL cholesterol of rats in each of the above groups were measured. The results were as shown in Table 1.

As is clear from the above results, compared to the control group that received only corn oil, the test group that received Japanese mountain ginseng had
A significant decrease in serum GOT is observed.

The results of measuring liver lipids are shown in Table 2.

Table 2 a indicates P<0.01.

As is clear from the above results, neutral fat (T.

G) showed a marked decreasing trend in Test Group 1, total cholesterol (T, C) significantly decreased in the Test Group, especially Test 1 Group, and lipid peroxide showed a decreasing trend in the Test Group.

As described above, the pharmaceutical composition of the present invention is highly effective in improving mild liver damage and fat accumulation in the liver caused by administration of lipid peroxide.

In addition, 3'-acetoxy-4'-angeloxy-31°4'-dihydroceserine and 3'-acetonacy4'-senecyoxy-, which are one of the components contained in Japanese ginseng,
3',4'-Dihydroceserine inhibits lipolysis caused by adrenaline, which is a counterhormone to insulin, but it has no effect on fat synthesis caused by insulin, so it only inhibits adrenaline, which is a sympathetic system, and has a subtext. The fact that it has no effect on the action of insulin, which is connected to the sensitive system, is due to the physiological effect of adrenaline, which is the constriction of blood vessels, which causes high blood pressure, and the secretion of adrenaline that is increased due to stress, etc., which causes hyperglycemia, etc. improve symptoms.

Patent applicant Takashi Takagi - Agent Masu Tebori (and 1 other person)

Claims (1)

[Claims] ■ A pharmaceutical composition characterized by containing Japanese ginseng as an active ingredient